CymaBay Therapeutics Inc. (CBAY): Price and Financial Metrics
GET POWR RATINGS... FREE!
CBAY Stock Price Chart Interactive Chart >
CBAY Price/Volume Stats
| Current price | $8.35 | 52-week high | $8.75 |
| Prev. close | $8.55 | 52-week low | $1.67 |
| Day low | $8.23 | Volume | 1,263,800 |
| Day high | $8.60 | Avg. volume | 1,649,000 |
| 50-day MA | $5.68 | Dividend yield | N/A |
| 200-day MA | $3.73 | Market Cap | 707.09M |
CymaBay Therapeutics Inc. (CBAY) Company Bio
Cymabay Therapeutics, Inc. focuses on developing therapies to treat metabolic diseases. The company was formerly known as Metabolex, Inc. The company was founded in 1988 and is based in Newark, California.
Latest CBAY News From Around the Web
Below are the latest news stories about CYMABAY THERAPEUTICS INC that investors may wish to consider to help them evaluate CBAY as an investment opportunity.
CymaBay Therapeutics to Present at the SVB Securities Global Biopharma ConferenceNEWARK, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the SVB Securities Global Biopharma Conference. SVB Securities Global Biopharma ConferenceDate: Wednesday, February 15Time: 3:40 pm Eastern TimeLocation: VirtualFormat: Fireside ChatWebcast: http://ir.cymabay.com/events A |
CymaBay Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesNEWARK, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need announced the closing, on January 26, 2023, of its previously announced underwritten public offering of its common stock and pre-funded warrants. CymaBay sold 11,821,428 shares of its common stock in the offering, including 1,821,428 shares pursuant to the full exer |
CymaBay Announces Pricing of Public Offering of Common Stock and Pre-Funded WarrantsNEWARK, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need, today announced the pricing of its previously announced underwritten public offering of common stock and pre-funded warrants. CymaBay is selling 10,000,000 shares of common stock and pre-funded warrants to purchase 2,142,857 shares of common stock in the offering. |
CymaBay Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsNEWARK, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need, today announced that it has commenced an underwritten public offering of its common stock and pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by CymaBay. CymaBay intends to grant the underwriters a |
Investors’ Faith in CymaBay Therapeutics Inc. (CBAY) could reap rewards if they hold on for the long haulCymaBay Therapeutics Inc. (CBAY)’s stock is trading at $6.80 at the moment marking a rise of 4.38% from the last session close. As of this writing, shares are priced at 3.11% less than their 52-week high of $6.59, and 306.86% over their 52-week low of $1.67. Based on the past 30-day period, the stock price […] |
CBAY Price Returns
| 1-mo | 41.29% |
| 3-mo | 159.32% |
| 6-mo | 123.26% |
| 1-year | 170.23% |
| 3-year | 438.71% |
| 5-year | -30.42% |
| YTD | 33.17% |
| 2022 | 85.50% |
| 2021 | -41.11% |
| 2020 | 192.86% |
| 2019 | -75.10% |
| 2018 | -14.46% |
Loading social stream, please wait...